
News|Articles|March 1, 2008
FDA pipeline preview, March 2008
FDA-related information through March 2008 on C1 inhibitor, ferric carboxymaltose injection, lovastatin, carbidopa/levodopa extended release, vigabatrin, bortezomib, peginterferon alfa-2b, elesclomol, triphendiol, VQD-002
Advertisement
Complete response letter
Recommended for approval
Nonapprovable designations
Fast-track designations
Priority review
Orphan drug designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Sanofi acquires Dynavax for $2.2 billion to bolster vaccine portfolio
2
Patients may not see savings from new Medicare drug programs
3
FDA accepts NDA for gedatolisib, Celcuity’s investigational breast cancer treatment
4
Why Timing, Access and Interpretation Matter in Oncology Biomarker Testing
5




















































